Fintel reports that on August 1, 2025, HC Wainwright & Co. downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Zynex Inc (NASDAQ:ZYXI) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $27.38 million, and the earnings are expected to come in at -$0.20 per ...

Zynex (ZYXI) delivered earnings and revenue surprises of -60.00% and -17.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Q2 2025 Earnings Call Transcript July 31, 2025 Zynex, Inc. misses on earnings expectations. Reported EPS is $-0.66 EPS, expectations were $-0.13. Operator: Good afternoon, ladies and gentlemen, and ...

An announcement from Zynex ( (ZYXI) ) is now available.

Zynex (NASDAQ:ZYXI), a medical technology company specializing in non-opioid pain management devices, issued its second quarter 2025 results on July 31, 2025. The release highligh ...

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of ...

Shareholder rights law firm Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors ...

ENGLEWOOD, Colo., July 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for ...

View Zynex, Inc. ZYXI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Zynex, Inc. reports Q2 2025 earnings with a $40M cost-reduction plan, leadership transitions, and FDA progress on its NiCO pulse oximeter.